Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis

Aim: Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P1,4,5, and S1P1,5 receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC). No head-to-head trial data exist between the two treatments. W...

Full description

Saved in:
Bibliographic Details
Main Authors: Vipul Jairath, Tim Raine, Thomas P Leahy, Ravi Potluri, Karolina Wosik, David Gruben, Joseph C Cappelleri, Peter Hur, Lauren Bartolome
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-02-01
Series:Journal of Comparative Effectiveness Research
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!